Correction: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective (Respiratory Research (2018) 19 (224) DOI: 10.1186/s12931-018-0916-7)

  1. Driessen, M.T.
  2. Whalen, J.
  3. Buguth, B.S.
  4. Vallejo-Aparicio, L.A.
  5. Naya, I.P.
  6. Asukai, Y.
  7. Alcázar-Navarrete, B.
  8. Miravitlles, M.
  9. García-Río, F.
  10. Risebrough, N.A.
Zeitschrift:
Respiratory Research

ISSN: 1465-993X,  1465-9921

Datum der Publikation: 2019

Ausgabe: 20

Nummer: 1

Art: Erratum

DOI: 10.1186/S12931-019-0985-2 GOOGLE SCHOLAR lock_openOpen Access editor

Ziele für nachhaltige Entwicklung

Datenquelle: Scopus